Literature DB >> 25895111

Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's Disease.

Fenling Fan1, Piyushkumar A Mundra, Lu Fang, Abby Galvin, Xiao Lei Moore, Jacquelyn M Weir, Gerard Wong, David A White, Jaye Chin-Dusting, Miles P Sparrow, Peter J Meikle, Anthony M Dart.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD), which encompasses ulcerative colitis (UC) and Crohn's disease (CD), is believed to be caused by abnormal host immune responses to the intestinal microbiome. However, the precise etiology of IBD remains unknown. Lipid metabolism and signaling are suggested to play important roles in inflammation with significant implications for IBD. In this study, we aimed to characterize lipidomic profiles in IBD with comparison between healthy controls, UC, and CD.
METHODS: Patients with IBD (n = 40, UC: 16 and CD: 24) and age- and gender-matched healthy volunteers (n = 84) were recruited. Plasma lipid profiles containing 333 lipid species were measured using electrospray ionization-tandem mass spectrometry.
RESULTS: A total of 86 individual lipid species were significantly changed in CD compared with controls (78 decreased while 8 increased), with the majority belonging to the ether lipids including the alkylphospholipids (alkylphosphatidylcholine and alkylphosphatidylethanolamine) and plasmalogens (alkenylphosphatidylcholine and alkenylphosphatidylethanolamine). Of these 86 lipid species, 33 remained significantly and negatively associated with CD after adjusting for age, sex, waist circumference, current smoking, and diastolic blood pressure in logistic regression. In contrast, only 5 lipid species significantly differed between UC and controls.
CONCLUSIONS: We demonstrate that a number of ether lipids (alkylphospholipid and plasmalogens) are significantly and negatively associated with CD. These alterations of lipid profiles particularly plasmalogens may contribute to the pathogenesis of IBD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25895111     DOI: 10.1097/MIB.0000000000000394

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

1.  Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn's Disease.

Authors:  Arshdeep Singh; Vandana Midha; Ramit Mahajan; Shruti Verma; Chandan Kakkar; Jasmine Grover; Dharmatma Singh; Ramandeep Kaur; Abhishek Masih; Namita Bansal; Catherine Wall; Ajit Sood
Journal:  Dig Dis Sci       Date:  2022-09-05       Impact factor: 3.487

2.  Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets.

Authors:  Antonio F Di'Narzo; Sander M Houten; Roman Kosoy; Ruiqi Huang; Frédéric M Vaz; Ruixue Hou; Gabrielle Wei; Wenhui Wang; Phillip H Comella; Tetyana Dodatko; Eduard Rogatsky; Aleksandar Stojmirovic; Carrie Brodmerkel; Jacqueline Perrigoue; Amy Hart; Mark Curran; Joshua R Friedman; Jun Zhu; Manasi Agrawal; Judy Cho; Ryan Ungaro; Marla C Dubinsky; Bruce E Sands; Mayte Suárez-Fariñas; Eric E Schadt; Jean-Frédéric Colombel; Andrew Kasarskis; Ke Hao; Carmen Argmann
Journal:  Gastroenterology       Date:  2021-11-13       Impact factor: 33.883

3.  Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Caroline T Brown; Amy K Motley; Sara N Horst; Christopher S Williams; Tatsuki Koyama; Zhiguo Zhao; Dawn W Adams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Metabolomics       Date:  2017-12-29       Impact factor: 4.290

4.  Detection of Independent Associations of Plasma Lipidomic Parameters with Insulin Sensitivity Indices Using Data Mining Methodology.

Authors:  Steffi Kopprasch; Srirangan Dheban; Kai Schuhmann; Aimin Xu; Klaus-Martin Schulte; Charmaine J Simeonovic; Peter E H Schwarz; Stefan R Bornstein; Andrej Shevchenko; Juergen Graessler
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

5.  Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia.

Authors:  Joon Seo Lim; Mi Young Lim; Yongbin Choi; GwangPyo Ko
Journal:  Mol Brain       Date:  2017-04-20       Impact factor: 4.041

6.  The potential of metabolic and lipid profiling in inflammatory bowel diseases: A pilot study.

Authors:  Cristian Tefas; Lidia Ciobanu; Marcel Tanțău; Corina Moraru; Carmen Socaciu
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

7.  Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment.

Authors:  Katja Kalenyak; Romy M Heilmann; Chris H A van de Lest; Jos F Brouwers; Iwan A Burgener
Journal:  PLoS One       Date:  2019-04-16       Impact factor: 3.240

8.  Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels.

Authors:  Antonio Murgia; Christine Hinz; Sonia Liggi; Jùlìa Denes; Zoe Hall; James West; Maria Laura Santoru; Cristina Piras; Cristina Manis; Paolo Usai; Luigi Atzori; Julian L Griffin; Pierluigi Caboni
Journal:  Metabolomics       Date:  2018-10-10       Impact factor: 4.290

9.  Measurement of Ether Phospholipids in Human Plasma with HPLC-ELSD and LC/ESI-MS After Hydrolysis of Plasma with Phospholipase A1.

Authors:  Shiro Mawatari; Seira Hazeyama; Takehiko Fujino
Journal:  Lipids       Date:  2016-07-07       Impact factor: 1.880

Review 10.  Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.

Authors:  Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.